Eikon Therapeutics
- Health & Biotech
- Millbrae, CA, US
- Founded 2019
- Public
- eikontx.com
Clinical-stage biotech combining engineering with molecular and cell biology to speed up drug discovery and development; listed on Nasdaq in 2026.
$732MEquity raised in 2025–20262025 $351M · 2026 $381M · 2 equity rounds
$732MEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 2 rounds · 2 sources · newest first
Earlier rounds not yet sourced. Eikon Therapeutics was founded in 2019 and raised before 26 Feb 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Initial public offering (Nasdaq: EIKN)Amount$381MPost-money—✓ Confirmed
- Series D (initial closing)Amount$351MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 11
- Alexandria Venture Investments
- AME Cloud Ventures
- E15 VC
- Foresite Capital
- General Catalyst
- Lux Capital
- Soros Capital
- StepStone Group
- T. Rowe Price
- The Column Group
- UC Investments
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
CognitionAI Apps · $3.4B in 2025–2026Shared: Lux Capital, General Catalyst +1HadrianDefense · $1.8B in 2025–2026Shared: Lux Capital, StepStone Group +1Modal LabsAI Infra · $1.2B in 2025–2026Shared: Lux Capital, General CatalystZeptoConsumer · $450M in 2025–2026Shared: General Catalyst, StepStone GroupCloakedCyber · $375M in 2025–2026Shared: Lux Capital, General CatalystRampFintech · $3.6B in 2025–2026Shared: Lux Capital, General Catalyst +1
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Eikon Therapeutics and its logo are trademarks of their owners, used here for identification only.
